Vontobel Holding Ltd. Grows Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)

Vontobel Holding Ltd. grew its position in Sutro Biopharma, Inc. (NASDAQ:STRO) by 66.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,000 shares of the company’s stock after acquiring an additional 10,000 shares during the quarter. Vontobel Holding Ltd.’s holdings in Sutro Biopharma were worth $46,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new position in Sutro Biopharma in the 4th quarter worth about $32,000. SG Americas Securities LLC boosted its stake in Sutro Biopharma by 16.6% in the 4th quarter. SG Americas Securities LLC now owns 40,432 shares of the company’s stock worth $74,000 after purchasing an additional 5,770 shares in the last quarter. Virtu Financial LLC acquired a new stake in Sutro Biopharma in the 3rd quarter worth approximately $77,000. Barclays PLC boosted its stake in Sutro Biopharma by 385.3% in the 3rd quarter. Barclays PLC now owns 273,019 shares of the company’s stock worth $944,000 after purchasing an additional 216,757 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Sutro Biopharma by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,856,956 shares of the company’s stock worth $6,426,000 after buying an additional 132,015 shares during the last quarter. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on STRO. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Sutro Biopharma in a research note on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 target price on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price target on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $11.13.

Sutro Biopharma Trading Down 3.3 %

STRO stock opened at $1.77 on Friday. Sutro Biopharma, Inc. has a twelve month low of $1.51 and a twelve month high of $6.13. The business has a 50 day simple moving average of $1.90 and a 200-day simple moving average of $3.01. The company has a market capitalization of $145.95 million, a P/E ratio of -1.10 and a beta of 1.15.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.